Literature DB >> 7480650

Enhanced radiation-induced cell killing by carboplatin in cells of repair-proficient and repair-deficient cell lines.

L Yang1, E B Douple, J A O'Hara, R A Crabtree, A Eastman.   

Abstract

The objective of this study was to determine whether a deficiency for either one of two repair processes influences the phenomenon of enhancement of radiation-induced cell killing by carboplatin which has been reported previously in one cell line (V79) and which is presumably a result of an interaction between these two therapeutic modalities. Cell killing was enhanced in cells of four cell lines when the cells were exposed to carboplatin before and during irradiation in either air or hypoxia. In cell lines proficient in both excision repair and DNA double-strand break repair (K1 and AA8), and in a cell line deficient in nucleotide excision repair (UV41), the enhancement was characterized as both a reduction in the shoulder region of the survival curves indicated by a reduced Dq and a reduction in D0 in the terminal region of the survival curves determined for cells exposed in air and under hypoxic conditions. Only the latter effect was observed in a cell line deficient in DNA double-strand break repair (xrs-5). The survival curves were fitted to the data using the repair saturation model and a computer program developed by N. Albright (Radiat. Res. 118, 112-130, 1989). In hypoxia, the reductions in Dq were as great as from 7.0 Gy to 2.1 Gy, 3.3 Gy to 0 Gy and 1.7 Gy to 0 Gy for K1, AA8 and UV41 cells, respectively. Sensitizer enhancement ratios ranged from 1.3 to 1.7 and were similar for irradiation in air and under hypoxic conditions. This enhanced cell killing by carboplatin combined with radiation required levels of the drug sufficient to produce cytotoxicity by the drug alone as exemplified by the UV41 cell line, which is intrinsically sensitive to carboplatin and in which 1/30 of the drug concentration required for the other cell lines produced an enhanced cell killing at an equitoxic dose of only 5 microM.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7480650

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  9 in total

1.  Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study.

Authors:  Regina I Jakacki; Peter C Burger; Tianni Zhou; Emiko J Holmes; Mehmet Kocak; Arzu Onar; Joel Goldwein; Minesh Mehta; Roger J Packer; Nancy Tarbell; Charles Fitz; Gilbert Vezina; Joanne Hilden; Ian F Pollack
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain.

Authors:  Gabriel Charest; Léon Sanche; David Fortin; David Mathieu; Benoit Paquette
Journal:  J Neurooncol       Date:  2013-09-13       Impact factor: 4.130

3.  Glioblastoma treatment: bypassing the toxicity of platinum compounds by using liposomal formulation and increasing treatment efficiency with concomitant radiotherapy.

Authors:  Gabriel Charest; Léon Sanche; David Fortin; David Mathieu; Benoit Paquette
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-26       Impact factor: 7.038

4.  Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study.

Authors:  Najat C Daw; Yueh-Yun Chi; John A Kalapurakal; Yeonil Kim; Fredric A Hoffer; James I Geller; Elizabeth J Perlman; Peter F Ehrlich; Elizabeth A Mullen; Anne B Warwick; Paul E Grundy; Arnold C Paulino; Eric Gratias; Deborah Ward; James R Anderson; Geetika Khanna; Brett Tornwall; Conrad V Fernandez; Jeffrey S Dome
Journal:  J Clin Oncol       Date:  2020-03-05       Impact factor: 44.544

5.  A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest.

Authors:  C M George; D J Haraf; A M Mauer; S A Krauss; P C Hoffman; C M Rudin; L Szeto; E E Vokes
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

6.  Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: a report from the Children's Oncology Group.

Authors:  Regina I Jakacki; Peter C Burger; Mehmet Kocak; James M Boyett; Joel Goldwein; Minesh Mehta; Roger J Packer; Nancy J Tarbell; Ian F Pollack
Journal:  Pediatr Blood Cancer       Date:  2015-02-19       Impact factor: 3.167

7.  Daily low-dose carboplatin as a radiation sensitizer for newly diagnosed malignant glioma.

Authors:  K Peterson; G Harsh; P G Fisher; J Adler; Q Le
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

8.  Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation.

Authors:  Gabriel Charest; Benoit Paquette; David Fortin; David Mathieu; Léon Sanche
Journal:  J Neurooncol       Date:  2009-09-17       Impact factor: 4.130

9.  Gemcitabine and carboplatin demonstrate synergistic cytotoxicity in cervical cancer cells by inhibiting DNA synthesis and increasing cell apoptosis.

Authors:  Guixiu Jin; Jing Zhao; Hongyan Qi; Meng Lou; Xia Liu; Yu Qu; Lingjun Zhao; Weifeng Zhang; Jimin Shao; Huizhen Zhong
Journal:  Onco Targets Ther       Date:  2013-11-25       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.